Accession Number : AD1020593

Title :   Promoter-Based Theranostics for Prostate Cancer

Descriptive Note : Technical Report,15 Sep 2014,14 Mar 2016

Corporate Author : Johns Hopkins UniversityBaltimore Baltimore United States

Personal Author(s) : Pomper,Martin

Full Text :

Report Date : 01 Jun 2016

Pagination or Media Count : 13

Abstract : We created new molecular-genetic expression vectors for efficient, non-invasive diagnosis and targeted radiopharmaceutical therapy of prostate cancer (PC). The diagnosis vector consists of the tumor-specific PEG-promoter (PEG-Prom) and cDNA of human chorionic gonadotropin beta chain (betahCG) as a reporter. We showed that transfection of the diagnostic vector to PC cells successfully produced detectable betahCG in the media by over-the-counter pregnancy kit and ELISA. We also showed that systemic, non-viral delivery of the vector to mice bearing human metastatic PC tumors produced detectable betahCG in serum and urine of the animals. The therapeutic vector has the PEG-Prom and HSV1-tk as a therapeutic gene. We also developed this therapeutic vector into clinically compatible version to comply with FDA regulation for later clinical transition. Mice with micrometastatic PC treated with [sup 211At] FAAU following systemic administration of the clinical vector showed significant delay in tumor development compared with untreated control. Healthy mice treated with the same therapeutic dose of [sup 211At] FAAU did not show any toxicity for 1 year.

Descriptors :   prostate cancer , Disease vectors , therapeutics , cell line , mice , metastasis , Radiotherapy , DIAGNOSTIC IMAGING

Distribution Statement : APPROVED FOR PUBLIC RELEASE